Free tool
FAERS Monitor: Betapace
Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019865 or its brand name (Betapace, Sotalol Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
3,865
Serious
3,025
78% of reports
Hospitalization
1,677
Death reported
400
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- atrial fibrillation355
- drug ineffective220
- dyspnoea219
- dizziness189
- hypotension189
- fatigue183
- nausea182
- electrocardiogram qt prolonged157
- asthenia149
- diarrhoea142
- bradycardia137
- fall123
- drug interaction117
- chest pain105
- death105
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 139 |
| 2005 | 92 |
| 2006 | 210 |
| 2007 | 283 |
| 2008 | 97 |
| 2009 | 178 |
| 2010 | 133 |
| 2011 | 165 |
| 2012 | 198 |
| 2013 | 122 |
| 2014 | 166 |
| 2015 | 142 |
| 2016 | 146 |
| 2017 | 168 |
| 2018 | 187 |
| 2019 | 187 |
| 2020 | 143 |
| 2021 | 127 |
| 2022 | 170 |
| 2023 | 167 |
| 2024 | 210 |
| 2025 | 267 |
| 2026 | 168 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,294 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| electrocardiogram qt prolongedSignal | 157 | 23.9 | 20.5 | 3,406 |
| atrial fibrillationSignal | 355 | 19.9 | 18.0 | 6,362 |
| hypotensionSignal | 189 | 5.1 | 4.5 | 630 |
| drug interactionSignal | 117 | 4.0 | 3.4 | 264 |
| astheniaSignal | 149 | 2.2 | 1.8 | 93 |
| dyspnoeaSignal | 219 | 2.1 | 1.9 | 129 |
| dizzinessSignal | 189 | 2.1 | 1.8 | 105 |
| fallSignal | 123 | 2.0 | 1.7 | 63 |
| fatigue | 183 | 1.3 | 1.1 | 11 |
| nausea | 182 | 1.3 | 1.1 | 9 |
| diarrhoea | 142 | 1.2 | 1.0 | 5 |
| drug ineffective | 220 | 0.9 | 0.8 | 2 |
| death | 105 | 0.7 | 0.5 | 18 |
| bradycardia | 137 | 0.0 | 0.0 | 740,723 |
| chest pain | 105 | 0.0 | 0.0 | 566,439 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.